MENU
+Compare
HELX
ETF ticker: BATS
AS OF
Jul 17, 11:33 AM (EDT)
Price
$27.72
Change
+$0.14 (+0.51%)
Net Assets
12.31M

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HELX with price predictions
Jul 16, 2025

HELX's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for HELX moved out of overbought territory on July 11, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HELX as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HELX turned negative on July 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HELX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HELX broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for HELX crossed bullishly above the 50-day moving average on June 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 238 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH), Sarepta Therapeutics (NASDAQ:SRPT), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 34.69B. The market cap for tickers in the group ranges from 180.95M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is VYGR at 180.95M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 16%. For the same ETF, the average monthly price growth was 27%, and the average quarterly price growth was 55%. INSM experienced the highest price growth at 8%, while RARE experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was -6%. For the same stocks of the ETF, the average monthly volume growth was -3% and the average quarterly volume growth was 35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 74
Price Growth Rating: 57
SMR Rating: 80
Profit Risk Rating: 80
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com